Fresenius Medical Care AG & Co. KGaA

FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.

seekingalpha.com - 2026-07-11 05:28:48

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.

zacks.com - 2026-07-08 15:05:27

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

zacks.com - 2026-06-23 14:21:09

One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.

newsfilecorp.com - 2026-06-22 05:00:00

Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.

newsfilecorp.com - 2026-06-15 05:00:00

FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.

zacks.com - 2026-06-08 15:56:07

Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.

zacks.com - 2026-06-05 12:35:26

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.

prnewswire.com - 2026-06-03 08:00:00

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.

prnewswire.com - 2026-05-28 07:00:00

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.

prnewswire.com - 2026-05-27 09:05:00

Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start.

prnewswire.com - 2026-05-26 07:00:00

Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Dean Hanisch, Chief Executive Officer, Focus Graphite Inc. ("Focus Graphite Advanced Materials" or the "Company") (TSXV: FMS), shares the Company's story in an interview with TMX Group. Cannot view this video?

newsfilecorp.com - 2026-05-21 15:01:00

Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care PR Newswire

gurufocus.com - 2026-05-21 11:00:00

Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026 EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs BAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid‑term financial and strategic targets set for 2025.

prnewswire.com - 2026-05-21 10:13:00

Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer PR Newswire BAD HOMBURG, Germany, May 2

gurufocus.com - 2026-05-20 14:00:00

BAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, today has reappointed Chief Financial Officer (CFO) and Management Board Member Martin Fischer (49) for a period of five years until 2031. Michael Sen, Chairman of the Supervisory Board, commented, "Martin Fischer has demonstrated strong and consistent leadership and has further strengthened Fresenius Medical Care's governance, transparency, and financial discipline.

prnewswire.com - 2026-05-20 13:00:00

Fresenius Medical's shares rise after Q1 earnings miss estimates as margin expansion and FME25+ savings support operating income growth.

zacks.com - 2026-05-06 12:41:15

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 16:01:17

Fresenius Medical Care is undervalued at a sub-10x P/E despite 7-9% AEPS growth and improved fundamentals. FMS has achieved 300-400 bps margin expansion, €800M+ in savings, and reduced leverage to 2.5x, supporting a more robust investment-grade profile. Even with flat or low growth, FMS offers 40-60% multi-year upside to a $29/share price target, justifying a 'Buy' rating.

seekingalpha.com - 2026-05-05 12:09:52

Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22% Earnings per share2 (EPS) increased by 16%, supported by the share buyback program FY 2026 outlook confirmed BAD HOMBURG, Germany, May 5, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giza, Chief Executive Officer of Fresenius Medical Care.

prnewswire.com - 2026-05-05 07:00:00

The dialysis specialist started restructuring its U.S. network by exiting 64 of up to 100 clinics.

wsj.com - 2026-05-05 03:22:00

Fresenius Medical Care said ​on Tuesday its ‌revenue fell 6% in the first ​quarter of ​2026, weighed down by ⁠significant currency ​effects, mainly from ​the weak U.S. dollar, and recent divestitures.

reuters.com - 2026-05-05 01:08:57